Daewoong Seeks FDA Approval for Botulinum Toxin
Daewoong Pharmaceutical’s botulinum toxin Nabota is expected to hit the US market by the end of 2018, fueling competition among rivals amid a near monopoly of Allergan.
Read MorePosted by Debbie Overman | May 19, 2017 | Rejuvenation |
Daewoong Pharmaceutical’s botulinum toxin Nabota is expected to hit the US market by the end of 2018, fueling competition among rivals amid a near monopoly of Allergan.
Read MorePosted by Debbie Overman | Apr 27, 2017 | Imaging, Research, Skin Conditions |
Botulinum Toxin Type A (Btx-A) treatment for Raynaud’s phenomenon (RP) may not be effective for all patients diagnosed with scleroderma, according to researchers.
Read MorePosted by Debbie Overman | Feb 3, 2017 | Body Makeover, Botox |
A new study reveals a potential benefit of Botox which may bring a new hope for patients who will undergo surgical repair of the rotator cuff.
Read MorePosted by Debbie Overman | Apr 14, 2016 | Research |
ALPHAEON Corp, Irvine, Calif, chose the recent American Society of Aesthetic Plastic Surgery meeting in Las Vegas to share its positive findings regarding two phase III clinical trials.
Read MorePosted by Debbie Overman | Jan 27, 2016 | Research |
A recent study helps back up the suggestion that using hyaluronic acid (HA) dermal fillers together with botulinum neurotoxin-A (BoNT-A) may help the fillers last longer.
Read More